GlassScriptPhysician profile
Fredric Jaffe
NPI 1043234008
$1,323.74
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $52.02 · 2021: $45.83 · 2022: $233 · 2023: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $208.64 | 2022-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $195.78 | 2020-2023 | Wakix |
| Insmed, INC. | $122.15 | 2022-2023 | Arikayce |
| Jazz Pharmaceuticals INC. | $97.97 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $92.21 | 2022-2023 | Tezspire, Breztri, Symbicort |
| Amgen INC. | $81.53 | 2022-2023 | Tezspire |
| Mallinckrodt Hospital Products INC. | $77.38 | 2023 | Acthar |
| Actelion Pharmaceuticals US, INC. | $71.66 | 2021-2023 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $64.32 | 2023 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.89 | 2023 | Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $41.06 | 2022-2023 | Belsomra |
| Philips North America LLC | $35.39 | 2023 | |
| Baxter Healthcare | $30.35 | 2022 | |
| Ani Pharmaceuticals, INC. | $30.11 | 2023 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $26.29 | 2023 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $24.79 | 2023 | Quviviq |
| Pulmonx Corporation | $22.26 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| United Therapeutics Corporation | $22.06 | 2022 | |
| Resmed Corp | $18.85 | 2023 | |
| Mylan Specialty L.P. | $13.05 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredric Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.